Targeted drug delivery of Sunitinib Malate to tumor blood vessels by cRGD-chiotosan-gold nanoparticles

Saber, Mohaddeseh Mahmoudi; Bahrainian, Sara; Dinarvand, Rassoul; Atyabi, Fatemeh

doi:10.1016/j.ijpharm.2016.12.016

Cited by 54 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For chemotherapeutic drugs to reach tumor cells in vivo, they have to travel through the blood vessels [ 120 , 121 , 122 , 123 ]. Blood flow through a solid tumor is varied and disorganized [ 124 , 125 ].…”

Section: Tumor Microenvironmentmentioning

confidence: 99%

The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer

Senthebane

Rowe

Thomford

et al. 2017

IJMS

318

330

View full text Add to dashboard Cite

Chemoresistance is a leading cause of morbidity and mortality in cancer and it continues to be a challenge in cancer treatment. Chemoresistance is influenced by genetic and epigenetic alterations which affect drug uptake, metabolism and export of drugs at the cellular levels. While most research has focused on tumor cell autonomous mechanisms of chemoresistance, the tumor microenvironment has emerged as a key player in the development of chemoresistance and in malignant progression, thereby influencing the development of novel therapies in clinical oncology. It is not surprising that the study of the tumor microenvironment is now considered to be as important as the study of tumor cells. Recent advances in technological and analytical methods, especially ‘omics’ technologies, has made it possible to identify specific targets in tumor cells and within the tumor microenvironment to eradicate cancer. Tumors need constant support from previously ‘unsupportive’ microenvironments. Novel therapeutic strategies that inhibit such microenvironmental support to tumor cells would reduce chemoresistance and tumor relapse. Such strategies can target stromal cells, proteins released by stromal cells and non-cellular components such as the extracellular matrix (ECM) within the tumor microenvironment. Novel in vitro tumor biology models that recapitulate the in vivo tumor microenvironment such as multicellular tumor spheroids, biomimetic scaffolds and tumor organoids are being developed and are increasing our understanding of cancer cell-microenvironment interactions. This review offers an analysis of recent developments on the role of the tumor microenvironment in the development of chemoresistance and the strategies to overcome microenvironment-mediated chemoresistance. We propose a systematic analysis of the relationship between tumor cells and their respective tumor microenvironments and our data show that, to survive, cancer cells interact closely with tumor microenvironment components such as mesenchymal stem cells and the extracellular matrix.

show abstract

Section: Tumor Microenvironmentmentioning

confidence: 99%

The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer

Senthebane

Rowe

Thomford

et al. 2017

IJMS

318

330

View full text Add to dashboard Cite

show abstract

“…This allows for the attachment of thiols through cysteine residues that have been used to conjugate peptides directly to the gold core or to conjugate a peptide onto a linker. 100,101,108 Most notably, the use of peptides allows site specific conjugation of the targeting moiety to AuNPs. This ensures that the peptides are attached to the AuNPs in a way that maintains their binding capability towards their target.…”

Section: Peptide Directed Gold Nanoparticlesmentioning

confidence: 99%

Active targeting of gold nanoparticles as cancer therapeutics

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Few studies have reported on polymeric NP formulations of STM [14,15]. Moreover, due to their small particle sizes, these polymeric systems have been found to be excellent carriers that enhance the solubility and bioavailability of various drugs with poor aqueous solubilities.…”

Section: Introductionmentioning

confidence: 99%

Characteristics and anticancer properties of Sunitinib malate-loaded poly-lactic-co-glycolic acid nanoparticles against human colon cancer HT-29 cells lines

Alshetaili¹,

Anwer²,

Alshahrani³

et al. 2018

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To develop poly-lactic-co-glycolic acid (PLGA)-based nanoparticles (NPs) for the delivery of sunitinib malate (STM) to colon cancer cells. Methods: Three different formulations (F1-F3) were developed by nano-precipitation technique using various concentrations of PLGA. The NPs were evaluated for particle size, polydispersity index, zeta potential, drug entrapment, and drug loading, using differential scanning calorimetry (DSC), Fouriertransform infrared spectroscopy (FTIR), x-ray diffraction (XRD), and scanning electron microscopy (SEM). Furthermore, in vitro drug release and anticancer studies were carried out on the formulations. Results: Among the three NPs, optimized NP (F3) of STM was chosen for in vitro anti-cancer study against H-29 human colon cancer cells lines based on its particle size (132.9 nm), PDI (0.115), zeta potential (-38.12 mV), entrapment efficiency (52.42 %), drug loading (5.24 %), and drug release (91.26 % in 48 h). A significant anti-cancer activity of the optimized NPs was observed, relative to free STM. Conclusion: These findings suggest that STM-loaded NPs possess significant anti-cancer activity against human colon cancer HT-29 cells lines.

show abstract

Targeted drug delivery of Sunitinib Malate to tumor blood vessels by cRGD-chiotosan-gold nanoparticles

Cited by 54 publications

References 36 publications

The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer

The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer

Active targeting of gold nanoparticles as cancer therapeutics

Characteristics and anticancer properties of Sunitinib malate-loaded poly-lactic-co-glycolic acid nanoparticles against human colon cancer HT-29 cells lines

Contact Info

Product

Resources

About